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ABSTRACT
Objectives: This study aims to determine how the expression of osteopontin is altered in the placenta percreta by compar-
ing osteopontin expression in normal placentas and placenta percreta tissues.
Material and methods: Placental tissues from hysterectomy materials which were histopathologically diagnosed with 
placenta percreta (study group, n = 20) and placental tissues obtained from normal term pregnancies (control group, 
n = 20) were immunohistochemically stained with osteopontin antibody. The groups were compared with respect to the 
intensity of cytoplasmic staining for osteopontin.
Results: The study and control groups were similar with respect to age, gravidity, parity, gestational age at birth, number 
of previous cesarean deliveries and curettages and (p > 0.05 for all). Immediate postoperative hemoglobin was significantly 
lower and the need for blood transfusion was significantly higher in the study group (p = 0.001 for both). Placental osteo-
pontin expression was significantly altered in the study group (p = 0.020). Negative staining for placental osteopontin was 
significantly more frequent in the placenta percreta group than the control group (9/20 vs 0/20, 45.0% vs 0%, p = 0.037). 
Conclusions: As reduced placental osteopontin expression was determined in the placenta percreta cases compared to the 
normal term placenta tissues, osteopontin can be considered to have a role in morbidly adherent placentation. This study 
is of value as the first study to investigate the changes in osteopontin expression in placenta percreta cases.
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INTRODUCTION
Morbidly adherent placenta (MAP) is the terminology 
generally used to define the abnormal adhesion of placen-
ta to the uterus. Depending on the depth of the placental 
adhesion, MAP can be described into accreta, increta, and 
percreta. The incidence of MAP has increased during the last 
50 years in parallel with the increasing rates of cesarean sec-
tion (CS), and therefore, MAP has become a significant cause 
of peripartum hemorrhage and thereby of maternal morbi-
dity and mortality in recent years [1, 2].
The defective decidua basalis, due to previous CS or cu-
rettages, or over-invasive trophoblastic cells or both of these 
factors are thought to have a role in the pathophysiology of 
MAP. More specifically, it has been hypothesized that MAP 
occurs as the interaction between maternal endometrium 
and migratory trophoblasts is impaired and uteroplacental 
circulation is interrupted [3–5].
Osteopontin (OPN) is an extracellular matrix glycopro-
tein which participates in cell proliferation and invasion 
and, thus, contributes to the tumorigenesis in several ty-
pes of malignancies [6–8]. Previously published studies 
have reported that the expression of osteopontin is evi-
dently present in the placental tissues of both mice and 
humans. Therefore, it has been suggested that osteopontin 
is somehow involved in the proliferation and invasion of 
trophoblasts during early placentation [9–11]. Although 
there have been several studies showing that the OPN plays 
a role in implantation and in placentation, no study has 
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been conducted to determine the level of OPN expression 
in cases with placenta percreta.
Objectives
This study aims to determine the role of OPN in the pa-
thogenesis of placenta percreta by comparing the expression 
of OPN in normal placenta and placenta percreta tissues.
MATERIAL AND METHODS
This case control study was approved by the local Institu-
tional Review Board and Ethics Committee of Kahramanma-
ras Sutcu Imam University Hospital where it was conducted.
The study group included placental tissues of 20 patients 
who underwent peripartum hysterectomy at the obstetrics 
department of the study center between June 2015 and De-
cember 2016 and who were histopathologically diagnosed 
with placenta percreta. The control group consisted of the 
placental tissues of 20 patients who had histopathologically 
normal term placentas and who underwent CS delivery due 
to various obstetric indications at the study center between 
June 2015 and December 2016. Written informed consent 
was obtained from all participants. Demographic and clinical 
characteristics of the reviewed patients were obtained from 
the medical records.
All of the histopathological and immunohistochemical 
examinations were carried out by two independent expe-
rienced histopathologists who were blinded to the demo-
graphic and clinical characteristics of the participants (A.Y. 
and S.K.). Placenta percreta was diagnosed when chorionic 
villi penetrated the uterine serosa [11]. 
Immunohistochemistry
Sections 4 µm thick in size were cut from the normal 
placental tissue samples in the control group and from 
the invasive sections of the placentas in the study group 
and then stained with the immunohistochemical method. 
Immunohistochemical staining of the sections was made 
with the biotin-streptavidin peroxidase method. One sec-
tion from each patient was evaluated. All the tissue sec-
tions were deparaffinised with xylol and were then passed 
through a series of ethanol solutions (100%, 96%, 80%) for 
dehydration. 
The samples were then washed with PBS and left for 
15 mins in 3% H2O2 for blockage of endogenous peroxidase 
activity, then treated with 10% bovine fetal serum to prevent 
non-specific connections. The sections were completely 
covered by drops of OPN anti-human monoclonal IgG an-
tibody (R&D System, MN, USA, 1:100 dilution) and left for 
1 hour [12]. All the samples were washed with PBS and after 
a secondary antibody IgG (R&D System, MN, USA) stage, 
a streptavidin peroxidase enzyme complex was applied. 
Diaminobenzidine was droppered chromogenously to bring 
it to a visible state and for counter staining, Mayer haemato-
xylin was used. For positive control purposes, breast cancer 
tissue slices were evaluated and for negative control, PBS 
was used instead of the primary antibody. 
Immunohistochemical scoring
Each section was evaluated under microscope (Nikon 
Eclipse 80i microscope connected to a DS-Fi1 camera using 
NIS-Elements) by a histologist (A.Y) and a pathologist (S.K) 
who were blinded to the clinical and histopathological 
diagnoses of the patients and photographs were taken at 
x100 magnification. 
For all the study subjects, immunohistochemical eva-
luation was made of 5 fields selected at random from the 
sections of placental tissue at x400 original magnification.The 
immunohistochemical staining of osteopontin was evaluated 
with a semi-quantitative scoring system in which cytoplasmic 
staining intensity was categorised as negative (0), weakly 
positive (1+), moderately positive (2+) or strongly positive 
(3+). A result of > 50% of the cells with strong staining was 
determined as strongly positive (3+), < 25% as weakly positive 
(1+) and 25–50% as moderately positive (2+) [13].
Statistical analysis
Collected data were analyzed by Statistical Package 
for Social Sciences version 18.0 (SPSS IBM Software, Ar-
monk, NY, USA). Continuous variables were expressed as 
mean ± standard deviation (range: minimum-maximum) 
whereas categorical variables were denoted as numbers 
or percentages where appropriate. Data distribution was 
evaluated by Kolmogorov–Smirnov test while independent 
samples t-test and chi-square test were used for compari-
sons. In order to avoid the risk of Type 1 errors, post hoc 
pairwise comparisons were made for the chi-square test. 
Two-tailed p values less than 0.05 were accepted to be 
statistically significant.
RESULTS
Demographic and clinical characteristics of the revie-
wed patients are shown in Table 1. The study and control 
groups were similar with respect to age, gravidity, parity, 
gestational age at birth, number of previous CS deliveries 
and D&C procedures and hemoglobin levels at hospital 
discharge (p > 0.05 for all). As expected, immediate posto-
perative hemoglobin was significantly lower and the need 
for blood transfusion was significantly higher in the placenta 
percreta patients (p = 0.001 for both). The average amount 
of blood transfusion was 4.6 ± 2.6 units (range: 4–8 units) 
in the placenta percreta group whereas only one patient in 
the control group received two units of blood transfusion.
Table 2 shows that placental OPN expression was signi-
ficantly altered in the placenta percreta group (p = 0.020). 
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DISCUSSION
The results of the current study showed that tropho-
blastic osteopontin expression was reduced in placenta 
percrata compared to normal term placenta.
The invasion of uterine tissue by trophoblastic cells in 
the process of normal placentation shows similarities to the 
behaviour of malignant cells in the formation of a tumour. 
That is, trophoblasts invade the endometrium as tumor cells 
Negative staining for placental OPN was significantly more 
frequent in the placenta percreta group than the control 
group (9/20 vs 0/20, 45.0% vs 0%, p = 0.037). 
Figure 1 demonstrates the weakly positive (1+) and 
strongly positive (3+) staining for OPN in placental tissues 
in the study group. Figure 2 displays the weakly positive 
(1+) and strongly positive (3+) staining for OPN in placental 
tissues in the control group. 




(n = 20) p
Age (years) 33.2 ± 3.8 30.6 ± 5.7 0.093
Gravidity 4.5 ± 0.9 3.8 ± 1.6 0.107
Parity 2.6 ± 0.8 2.0 ± 1.3 0.057
Previous curettages 0.4 ± 0.2 0.5 ± 0.2 0.728
Previous cesarean deliveries 2.0 ± 0.9 1.4 ± 1.0 0.061
Gestational age (weeks) 36.1 ± 5.2 38.2 ± 1.5 0.073
Postoperative hemoglobin [g/dL] 8.8 ± 1.1 11.0 ± 0.8 0.001*
Need for blood transfusion 16 (80.0%) 1 (5.0%) 0.001*
Hemoglobin at hospital discharge [g/dL] 11.5 ± 1.4 11.4 ± 1.3 0.695
* p < 0.05 was accepted to be statistically significant
Table 2. Immunohistochemical staining for placental osteopontin in the study and control groups
Cytoplasmic staining intensity* Study group(n = 20)
Control group
(n = 20) p
0 9 (45.0%) 0 (0.0%) χ2 = 4,333; p = 0.037†
1+ 5 (25.0%) 7 (35.0%) χ2 = 0,921; p = 0.337
2+ 2 (10.0%) 5 (25.0%) χ2 = 1,558; p = 0.212
3+ 4 (20.0%) 8 (40.0%) χ2 = 1,905; p = 0.168
χ2 = 5,380; p = 0.020†; *0 — negative staining, 1+ (weakly positive) — < 25% of the cells stained, 2+ (moderately positive) — 25%–50% of the cells stained; 3+ (strongly 
positive) — > 50% of the cells stained; †p < 0.05 was accepted to be statistically significant
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invade the adjacent tissues and metastasize [14]. However, 
the difference between normal placentation and malignant 
tumours is that the invasion of trophoblasts is kept under 
control with a complex process including cell adhesion 
molecules, the ligands of these adhesion molecules and 
the immune system [15].
Osteopontin (OPN) is a secreted glycoprotein with a role 
in cell-cell adhesion, cell-extra-cellular matrix (ECM) commu-
nication and cell migration. The binding of OPN to integrin, 
located in the membrane of uterine luminal epithelium cells, 
plays a role in the adhesion of the conceptus. In normal 
placenta, OPN is strongly present in the extravillous tro-
phoblasts and cytotrophoblasts of the villous trophoblasts 
which are capable of proliferation and invasiveness [10]. 
An in vitro study reported that decreased OPN expression 
might disturb trophoblastic growth and invasion so that 
spontaneous abortion may occur [16]. In addition to the role 
in early pregnancy, the expression of OPN in the placenta 
has been shown in the later weeks of pregnancy [17, 18]. 
When these findings are interpreted together, it has been 
suggested that OPN acts in trophoblastic proliferation and 
invasion, and, thus, placentation.
To the best of our knowledge, this is the first study which 
aims to investigate the role of OPN in the pathogenesis of 
placenta percreta. Our results indicated significantly we-
aker staining for OPN in placenta percreta when compared 
to normal placenta of similar gestational age. Since OPN 
expression is up-regulated in several malignancies, signifi-
cantly less OPN content in placenta percreta may appear as 
a contradictory finding [6, 8]. Defects in cellular adhesion 
molecule expression in cancer tissue has been shown to be 
associated with increased cellular invasion [19]. Supporting 
this information, in the placenta percreta cases of the current 
study, the reduced level of placental OPN expression might 
have decreased the decidual adhesion of trophoblasts and 
it can be suggested that in this way the trophoblasts could 
migrate more freely, forming an excessive invasion.
Supporting the findings of the current study, it has pre-
viously been shown that expression of OPN mRNA was 
decreased in gestational trophoblastic disease which is as-
sociated with an altered regulation of trophoblastic growth 
and invasion [20].
CONCLUSIONS
In conclusion, lowered expression of osteopontin seems 
to have a role in the pathogenesis of placenta percreta. This 
study is of value as the first study to investigate the chan-
ges in OPN expression in placenta percreta cases. Further 
research is warranted to clarify the role of osteopontin in 
the pathogenesis of placenta percreta. 
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